Compare Meta Platforms Inc (META) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs TransMedics Group Inc — how do they compare? Meta Platforms Inc trades at $718.67 (market cap $1.84T), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Meta Platforms Inc is far larger — about 671.5× TransMedics Group Inc's market cap, and Meta Platforms Inc pays a 0.29% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Meta Platforms Inc for 127 Days and TransMedics Group Inc for 24 Days on average.
| META | TMDX | |
|---|---|---|
Market Cap | $1.84T | $2.74B |
Volume | 15,887,049 | 949,331 |
Sector | Media | Health |
52-Week High | $777.59 | $150.42 |
52-Week Low | $525.72 | $61.99 |
Typical Hold Time | 127 Days | 24 Days |
Enterprise Value | $1.86T | $3.13B |
Dividend Yield | 0.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Meta Platforms (META) trades at $720.89, down 0.06% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with $201B revenue in 2025 and 29.84% net income margin, though Q2 2026 earnings missed expectations. Recent AI developments including the Muse Spark launch and a $21B CoreWeave deal highlight strategic positioning in artificial intelligence infrastructure.
Wall Street maintains strong bullish sentiment with 80% buy ratings and $781 consensus price target, representing 8% upside. Key risks include ongoing youth addiction litigation in Massachusetts and elevated capital expenditures for AI infrastructure. The stock presents growth potential through AI monetization but faces regulatory and execution challenges.
TransMedics Group (TMDX) trades at $79.00, down 2.55% amid bearish technical signals and mixed earnings performance. The stock shows strong fundamentals with 58.69% gross margins and 22.69% net income margins, though profitability declined year-over-year. Recent news highlights insider buying, CFO appointment, and ongoing legal investigations into fiduciary duties, creating conflicting sentiment signals.
While analyst consensus remains bullish with a $99.75 price target, near-term risks include margin pressure from heavy investments and legal uncertainties. The stock's current valuation at 20.47 P/E offers potential upside if execution improves, but investors face volatility from earnings misses and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
